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SUMMARY 14 
People living in areas with stable transmission of P. falciparum parasites acquire 15 
protective immunity to malaria over a number of years and following multiple disease 16 
episodes. Immunity acquired this way is mediated by IgG with specificity for parasite-17 
encoded, clonally variant surface antigens (VSA) on the surface of infected erythrocytes 18 
(IEs). However, women in endemic areas become susceptible to P. falciparum infection 19 
when they become pregnant, particularly for the first time, regardless of previously 20 
acquired protective immunity. This conundrum was resolved when it was observed that 21 
the selective placental accumulation of IEs that characterizes pregnancy-associated 22 
malaria (PAM) is caused by an immunologically and functionally unique subset of VSA 23 
(VSAPAM) that is only expressed by parasites infecting pregnant women, and that 24 
protective immunity to PAM is mediated by IgG with specificity for VSAPAM. In this 25 
review we summarize the research leading to the identification of the distinctly 26 
structured PfEMP1 variant VAR2CSA as the dominant PAM-type VSA and as the 27 
clinically most important target of the protective immune response to placental 28 
P. falciparum infection. 29 
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INTRODUCTION 33 
Plasmodium falciparum malaria is both the commonest and most serious form of 34 
malaria affecting humans, and is an infection of colossal medical and economic 35 
consequence (Sachs and Malaney 2002; Miller et al. 2002; Greenwood and 36 
Mutabingwa 2002). In areas of intense parasite transmission, severe P. falciparum 37 
malaria is concentrated among infants and young children, because acquisition of 38 
protective immunity causes malaria-related mortality and severe morbidity to decrease 39 
with increasing age. However, development of immunity is slow, and substantial 40 
protection is only achieved after a number of disease episodes. Even then, immunity is 41 
partial, and though severe morbidity is rare among adults, sterile protection is probably 42 
never achieved. Several studies have documented the efficacy of passive immunization 43 
of malaria patients with IgG from clinically immune adults, showing that antibodies 44 
targeting asexual blood-stage antigens are an important component of protective 45 
immunity acquired following natural exposure to P. falciparum parasites (Cohen, 46 
McGregor and Carrington 1961; McGregor, Carrington and Cohen 1963; Sabchareon et 47 
al. 1991). Trans-placental transfer of IgG also seems to be responsible for resistance to 48 
malaria for the first months of life in infants born to clinically immune mothers (Bruce-49 
Chwatt 1952). Antibodies with specificity for a number of antigens expressed by 50 
asexual blood-stage parasites are likely to contribute to this protection. However, 51 
parasite-encoded, clonally variant surface antigens (VSA) expressed on the surface of 52 
the infected erythrocytes (IEs) appear to be of particular importance (Marsh et al. 1989), 53 
and the intra- and inter-clonal diversity of VSA go a long way towards explaining the 54 
sluggish acquisition of immunological protection (reviewed by Hviid 2005). The 55 
general rule of P. falciparum malaria as a childhood disease in areas of intense parasite 56 
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transmission has one important exception that has attracted substantial attention in 57 
recent years: pregnancy-associated malaria (PAM). 58 
PREGNANCY-ASSOCIATED MALARIA 59 
It is a long-recognized fact that pregnant women are at increased risk of malaria, with 60 
adverse maternal and foetal consequences (reviewed by Duffy and Desowitz 2001). 61 
This pregnancy-related susceptibility is apparent despite previously acquired protective 62 
immunity, and even in malaria-endemic areas, P. falciparum infection is therefore both 63 
more prevalent and more severe in pregnant women than in their non-pregnant peers 64 
(Walton 1949). It has often been speculated that PAM is an unavoidable consequence of 65 
maternal immuno-suppression or -modulation to protect the foetal allograft from 66 
rejection (Menendez 1995). However, pregnancy-induced immune modulation mainly 67 
affects the cellular arm of immunity, whereas humoral immunity (upon which 68 
protection from malaria hinges) is largely unaffected (reviewed by Guilbert, Abbasi and 69 
Mosmann 2001). Furthermore, susceptibility to PAM is concentrated among women of 70 
low parity, in particular primigravidae (McGregor 1984). This suggests that 71 
susceptibility to PAM is due to a specific absence of immunity to a particular form or 72 
subset of P. falciparum parasites that can only infect pregnant women, and that 73 
protection against PAM-specific parasites is acquired following exposure to them 74 
during pregnancy in a manner similar to acquisition of protection from malaria in 75 
general. The hypothesis of a pregnancy-specific subset of P. falciparum is further 76 
supported by the facts that PAM is characterized by a selective accumulation of IEs in 77 
the placenta (Blacklock and Gordon 1925) and that pregnancy-associated parasitaemia 78 
generally resolves spontaneously shortly after expulsion of the placenta at 79 
delivery (Nguyen-Dinh et al. 1988).  80 
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PAM is caused by functionally and immunologically unique parasites 81 
Erythrocytes infected by mature (trophozoite and schizont) stages of P. falciparum 82 
parasites can bind to a range of different receptors in the host vasculature. The first 83 
adhesion receptor identified was CD36 (Barnwell, Ockenhouse and Knowles, II 1985; 84 
Ockenhouse et al. 1989), followed by a range of other molecules, including the 85 
proteoglycan chondroitin sulphate A (CSA) (Rogerson et al. 1995; Robert et al. 1995). 86 
The first direct piece of evidence in favour of the hypothesis of a discrete parasite subset 87 
being responsible for PAM was the finding that IEs isolated from the placenta of 88 
women with PAM exclusively bind to CSA, a receptor that is rarely – if ever – 89 
exploited as an adhesion receptor by P. falciparum-IEs in non-PAM infections (Fried 90 
and Duffy 1996). This key observation was followed by the similarly important 91 
observation that placental and CSA-adhering IEs are not only functionally but also 92 
immunologically distinct from all other IEs (Fried et al. 1998; Beeson et al. 1999; Ricke 93 
et al. 2000). As adhesion of IEs in general is mediated by VSA, these findings together 94 
pointed to a functionally and immunologically distinct subset of VSA that is exclusively 95 
expressed by placental and CSA-adhering parasites; a subset often referred to as 96 
VSAPAM.   97 
Protective immunity to PAM is mediated by IgG with specificity for PAM-specific 98 
VSA  99 
It is generally suspected that protective immunity to malaria depends on VSA-specific 100 
IgG that can interfere with receptor-specific IE adhesion (David et al. 1983; Udeinya et 101 
al. 1983), and that the piecemeal acquisition of protective immunity to malaria reflects 102 
the need to acquire a broad repertoire of such antibodies with specificity for a multitude 103 
of antigenically distinct VSA (Marsh and Howard 1986; Bull et al. 1998).  The 104 
 6
importance of VSAPAM in protective immunity against PAM was therefore reinforced 105 
when it was shown that serum antibodies can inhibit adhesion of IEs to CSA in a parity-106 
dependent manner (Fried et al. 1998; Ricke et al. 2000). In addition to inhibition of IE 107 
adhesion, opsonization and phagocytosis of IEs may also play an important role in 108 
protective immunity to PAM. The dominance of cytophilic subclasses among VSAPAM-109 
specific IgG (Megnekou et al. 2005; Elliott et al. 2005) and the finding of impaired 110 
opsonization of VSAPAM-expressing IEs in HIV-infected women (Mount et al. 2004; 111 
Keen et al. 2006) support this possibility. In any case, levels of VSAPAM-specific IgG at 112 
delivery correlate inversely with placental parasitaemia (Staalsoe et al. 2001), and direct 113 
and compelling evidence of the clinical importance of CSA adhesion-inhibitory as well 114 
as VSAPAM-specific IgG have recently become available (Duffy and Fried 2003; 115 
Staalsoe et al. 2004). 116 
Molecular identification of VSAPAM, 117 
Most efforts to identify VSAPAM in molecular terms have focused on the best-described 118 
family of VSA, P. falciparum erythrocyte membrane protein 1 (PfEMP1) (Leech et al. 119 
1984). These high-molecular weight antigens are encoded by the var multi-gene family 120 
(Baruch et al. 1995; Su et al. 1995; Smith et al. 1995). Scherf et al. (1998) observed 121 
transcription of a particular var gene, dubbed varCSA, in P. falciparum FCR3 selected for 122 
IE adhesion to CSA, and the Duffy-binding-like (DBL) 3- domain of the encoded 123 
PfEMP1 variant was found to have affinity for CSA (Buffet et al. 1999). Most 124 
P. falciparum genomes contain a var gene very similar to varCSA, and these related 125 
genes were grouped together in the var1csa sub-family of var genes (Salanti et al. 2002; 126 
Rowe et al. 2002). These findings, and the observation that var1csa is often highly 127 
transcribed by placental parasites (Fried and Duffy 2002), fitted the earlier prediction 128 
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(Fried et al. 1998) that the antigen mediating IE adhesion to CSA, and the suspected 129 
target of PAM-specific immunity, was conserved between parasite clones. However, a 130 
number of other findings do not support the hypothesis of VAR1CSA as a PAM-type 131 
VSA, or its involvement as a target of protective immunity against PAM. Thus, high 132 
transcription of var1csa is not restricted to placental and CSA-adhering parasites (Rowe 133 
et al. 2002; Kyes et al. 2003), and levels of VAR1CSA-specific IgG do not correlate 134 
with gender or parity, in contrast to expectation regarding VSAPAM-specific IgG (Jensen 135 
et al. 2003). Finally, the ability of IEs to adhere to CSA is maintained after disruption of 136 
var1csa (Andrews et al. 2003).  137 
An unusually structured gene, var2csa, is selectively transcribed by CSA-adhering 138 
and placental parasites 139 
The availability of the complete P. falciparum genome (Gardner et al. 2002) opened the 140 
possibility of more precise analysis of var gene transcription than had previously been 141 
possible with degenerate primers (Taylor et al. 2000). Taking this approach, Salanti et 142 
al. (2003) analyzed changes in var gene transcription in response to selection of NF54-143 
IEs for adhesion to CSA, which resulted in acquisition of the VSAPAM-type gender-144 
specific and parity-dependent IgG recognition pattern of selected IEs (Ricke et al. 145 
2000). The striking result was that the selection resulted in markedly increased and 146 
dominant transcription of a single, distinctly structured, var gene, PFL0030c (Salanti et 147 
al. 2003). PFE1640w, which belongs to the var1csa sub-family previously implicated in 148 
adhesion of IE to CSA, is a pseudo-gene in NF54/3D7, but data from other parasite 149 
lines have shown that selection for IE adhesion to CSA does not increase the abundance 150 
of var1csa transcripts (Salanti et al. 2003). Genes with high similarity to PFL0030c, and 151 
now grouped in the var2csa sub-family, appear to be present in all P. falciparum clones 152 
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and to be selectively transcribed by CSA-selected and placental parasites alike (Salanti 153 
et al. 2003; Duffy et al. 2005; Tuikue Ndam et al. 2005). The findings that several 154 
VAR2CSA domains have affinity for CSA (Gamain et al. 2005) and that disruption of 155 
var2csa interferes with the ability to acquire the CSA-adhering phenotype further 156 
supports the PAM-relevance of this sub-family (Viebig et al. 2005; Duffy et al. 2006). 157 
It is noteworthy that the var2csa response to CSA-selection had gone unnoticed in 158 
earlier studies because they used degenerate primers targeting DBL1- or DBL1- 159 
encoding sequences (Taylor et al. 2000; Fried and Duffy 2002); domains that are not 160 
present in VAR2CSA. 161 
VAR2CSA has the characteristics expected of VSAPAM  162 
The distinct structure of var2csa compared to other var genes corresponded well with 163 
the expected functional and antigenic uniqueness of the PAM-type VSA it was assumed 164 
to encode (Lavstsen et al. 2003; Kraemer and Smith 2003). Indeed, analysis of levels of 165 
VAR2CSA-specific IgG in P. falciparum-exposed adults confirmed the female-166 
restricted and parity-dependent pattern expected of VSAPAM (Salanti et al. 2004). 167 
Importantly, VAR2CSA is present on the surface of intact VSAPAM-type IEs and absent 168 
from the surface of IEs that do not have this phenotype (Salanti et al. 2004; Barfod et al. 169 
2006). Finally, we have shown that high plasma levels of VAR2CSA-specific IgG 170 
correlate with protection from adverse clinical consequences of PAM (Salanti et al. 171 
2004).  172 
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VAR2CSA appears to be the dominant target of the protective immune response to 173 
PAM 174 
The importance of VSA-specific IgG relative to IgG with other antigen specificities for 175 
clinical protection against P. falciparum malaria is unknown, but may be high (Marsh et 176 
al. 1989). A parallel issue is the importance of IgG with specificity for VAR2CSA 177 
relative to other VSAPAM specificities in protection against PAM. To address this latter 178 
question, we cloned memory B cells from recently pregnant, P. falciparum-exposed 179 
multigravidae, using a recently developed and highly efficient immortalization method 180 
(Traggiai et al. 2004). The clones were subsequently screened for production of 181 
VSAPAM-specific monoclonal IgG using a panel of IEs displaying the VSAPAM 182 
phenotype. All except one of the eight VSAPAM-specific monoclonals had specificity for 183 
either the DBL3-X or the DBL5- domain of VAR2CSA (Barfod et al. 2006). The 184 
characteristics of the remaining antibody suggest that it is also VAR2CSA-specific. 185 
Although var2csa is composed of alternating stretches of substantial and restricted 186 
interclonal diversity (Salanti et al. 2003; Trimnell et al. 2006; Dahlbäck et al. 2006), all 187 
the human monoclonal IgG antibodies targeted polymorphic rather than conserved 188 
epitopes (Barfod et al. 2006). This finding suggests that domains of IE surface-189 
expressed VAR2CSA that are accessible to protective antibodies are under selection 190 
pressure that favours polymorphism, in agreement with conclusions drawn from in 191 
silico analysis of var2csa (Trimnell et al. 2006; Dahlbäck et al. 2006). This pressure is 192 
most likely due to protective host immunity, supporting the clinical significance of the 193 
VAR2CSA-specific IgG response to PAM. 194 
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CONCLUDING REMARKS 195 
VAR1CSA (as well as several non-PfEMP1 antigens) continues to be implicated in the 196 
pathogenesis as well as in the protective immune response to pregnancy-specific 197 
P. falciparum infection (Chia et al. 2005; Badaut et al. 2006), and is being explored as a 198 
candidate for development of vaccines against PAM (Gamain et al. 2004; Chia et al. 199 
2005; Bir et al. 2006). However, from our perspective the bulk of current evidence 200 
identifies VAR2CSA as the main antigen mediating placental sequestration of 201 
P. falciparum-IEs and as the dominant and clinically most relevant target of the human 202 
IgG response to placental P. falciparum infection. 203 
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